Journal
Journal of Thoracic Oncology
Publication Date
10-1-2019
Volume
14
Issue
10
First Page
1828
Last Page
1838
Document Type
Open Access Publication
DOI
10.1016/j.jtho.2019.06.021
Rights and Permissions
Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, Kruger RG, Mohammad HP, Ballas MS, Dhar A, Govindan R. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi.org/10.1016/j.jtho.2019.06.021. Copyright 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
Recommended Citation
Bauer, Todd M; Besse, Benjamin; Martinez-Marti, Alex; Trigo, Jose Manuel; Moreno, Victor; Garrido, Pilar; Ferron-Brady, Geraldine; Wu, Yuehui; Park, Jennifer; Collingwood, Therese; Kruger, Ryan G; Mohammad, Helai P; Ballas, Marc S; Dhar, Arindam; and Govindan, Ramaswamy, "Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC." Journal of Thoracic Oncology. 14, 10. 1828 - 1838. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/11865
